Skip to content
Research/Peptides/FOXO4-DRI

FOXO4-DRI

D-Retro-Inverso-retro-inverso peptide. Blocks FOXO4-p53 interaction, induces apoptosis in senescent cells. Senolytic, clearance of "zombie cells".

Intelligence Profile

Safety Profile

Evidence Limitation: The safety profile of FOXO4-DRI is based entirely on preclinical studies in laboratory models and animal research. No human clinical trial safety data is currently available, representing a significant limitation in understanding its safety profile in humans.

Known Effects from Preclinical Studies

Based on animal and cellular studies, FOXO4-DRI appears to:

  • Target senescent cells by disrupting the FOXO4-p53 protein interaction
  • Promote apoptosis (cell death) specifically in senescent cells
  • Affect cellular pathways including p53 signaling and mitochondrial function

Potential Safety Concerns

Lack of Human Data: Without clinical trials, the following remain unknown:

  • Safe dosing ranges in humans
  • Acute and chronic toxicity profiles
  • Organ-specific adverse effects
  • Individual variation in response and tolerance

Theoretical Concerns Based on Mechanism:

  • Since FOXO4-DRI affects p53 signaling pathways that are crucial for normal cellular function, there may be risks to healthy cells
  • The compound's effects on apoptosis could potentially impact normal tissue regeneration and repair processes
  • Long-term consequences of senescent cell elimination are not fully understood

Contraindications and Special Populations

Evidence is insufficient to establish specific contraindications or identify populations who should avoid FOXO4-DRI. However, based on the compound's experimental nature and mechanism of action, particular caution would theoretically be warranted in:

  • Individuals with active malignancies (due to p53 pathway interactions)
  • Those with compromised immune systems
  • Pregnant or breastfeeding women
  • Pediatric populations

Drug Interactions

No drug interaction data is available from the current evidence. The compound's effects on cellular signaling pathways suggest potential for interactions, but specific interactions remain uncharacterized.

Clinical Development Status

FOXO4-DRI remains an investigational compound with no established safety profile in humans. All current evidence comes from laboratory and animal studies, which may not translate directly to human safety and efficacy.

Medical Disclaimer: This information is for educational purposes only and should not be used for treatment decisions. Consult healthcare professionals for medical advice regarding experimental therapies.

Free account required

Safety profile requires a free AXIFI account to access clinical data, safety profiles, and research papers.